Areas of Interest & Competitive Research Grants - Bristol Myers Squibb

Please note that during an open RFP submission window, clicking on a link to submit your research idea will take you to the FastTrack Investigator Portal and you will receive a message that you are leaving BMS.com. This is part of the normal process.

• If you are a potential investigator who is interested in seeking support to conduct independent research involving  Nivolumab  in Japan, Taiwan, or Korea, click here
• If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here.
• If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here
• If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here
• If you are a potential investigator who is interested in seeking support for independent research involving NKTR-214 (Bempegaldesleukin) & Nivolumab, click here

Melanoma – Relatlimab ISR Areas of Interest – 2021 RFP Cycle 1

In scope:

• Relatlimab + Nivolumab or other Relatlimab + Nivolumab-based combinations in metastatic patients with the highest unmet need (i.e., brain metastasis, high LDH, >3 sites of disease, poor PS, post PD1, non-cutaneous, etc.) regardless of BRAF status and line of therapy
• Understand biomarkers and translational mechanisms of response, resistance, and adverse events to Relatlimab + Nivolumab-based combinations
• Neoadjuvant/peri-adjuvant research with Relatlimab + nivolumab-based combinations, regardless of BRAF status, to understand tumor biology and improve patient outcomes
• Sequencing with Relatlimab + Nivolumab relative to other therapies (re-treatment and switch), regardless of BRAF status

Out of scope:

• Pediatric studies
• Studies investigating non-melanoma tumors
• Studies investigating Relatlimab as monotherapy
• Studies only including Nivolumab ± Ipilimumab in melanoma (Nivolumab ± Ipilimumab as comparator arm allowed)
• Each individual drug in Relatlimab + Nivolumab-based combination must have established phase 2 dose, otherwise considered out of scope

TYK2 (deucravacitinib) AOIs – RFP#2

In scope

• Deucravacitinib efficacy and safety in moderate to severe psoriasis, including patient sub-populations
• Demographics (e.g., ethnicity, race) 
• Body regions
• Psoriasis treatments (e.g., Systemic treatment naïve, switching from or adding on to topical therapy, switching from other oral systemic therapies
• Additional measures of response (eg, patient satisfaction, other Patient-Reported Outcomes)
• Clinical and biomarker proof-of-concept evidence with deucravacitinib in other dermatological immune-mediated diseases with evidence of involvement of TYK2-mediated pathways
• Nonclinical studies furthering the understanding of the role of TYK2 in immune mediated diseases

Out of scope

• Pediatric studies
• Combination with other disease modifying therapies 
• Alternative dosing regimens

FOR CAR T ASSETS 

• Based on the current manufacturing capacity for CAR T products, we are unable to consider ISR proposals that require the provision of CAR T product at this time. 
• We are accepting ISR proposals for CAR T based on the following Areas of Interest (AOIs)

Liso-cel AOIs

1. Decipher the optimal treatment sequence with liso-cel in DLBCL through real world evidence
   • What is the optimal sequencing of liso-cel with other available treatments?
   • What are the outcomes for patients who proceed to other therapies post liso-cel failure? 
2. Identify optimal bridging strategies to liso-cel in DLBCL including through real world evidence 
3. Evaluate outcomes in patients treated with liso-cel or other CAR T through real world evidence 
   • What are the outcomes in the commercial setting vs clinical trials?
   • What are the outcomes for those who do not experience grade 3+ CRS / NT, or other AEs?
   • Do interventions for CRS / NT (e.g., steroids, tocilizumab) impact outcomes?

Ide-cel AOIs

1. Evaluate use of ide-cel in triple class exposed RRMM through real world evidence
   • Evaluate predictors of response
   • Assess impact of bridging therapy
   • Understand longer-term outcomes with ide-cel
2. Evaluate safety profile to inform setting of care decisions through real world evidence
   • Assess mitigation and monitoring strategies for CRS & NT
   • Evaluate site of care and timing of release from hospital
   • Assess impact of long-term cytopenias
3. Evaluate sequencing in RRMM through real world evidence
   • Assess sequencing of ide-cel with respect to other anti-BCMA assets
   • Evaluate impact of prior treatments 
   • Assess outcomes of patients who receive other therapies post ide-cel failure

If you are an investigator who is interested in seeking support for independent research relating to CAR T (ide-cel or liso-cel), click here